scispace - formally typeset
Search or ask a question
Journal ArticleDOI

Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need

01 Apr 2017-Nature Reviews Microbiology (Nature Publishing Group)-Vol. 15, Iss: 4, pp 217-231
TL;DR: The combination of new drugs, new technologies and public health initiatives is essential for the management, and hopefully eventual elimination, of trypanosomatid diseases from the human population.
Abstract: The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected tropical diseases. These diseases are caused by parasitic trypanosomatids and range in severity from mild and self-curing to near invariably fatal. Public health advances have substantially decreased the effect of these diseases in recent decades but alone will not eliminate them. In this Review, we discuss why new drugs against trypanosomatids are required, approaches that are under investigation to develop new drugs and why the drug discovery pipeline remains essentially unfilled. In addition, we consider the important challenges to drug discovery strategies and the new technologies that can address them. The combination of new drugs, new technologies and public health initiatives is essential for the management, and hopefully eventual elimination, of trypanosomatid diseases from the human population.

Content maybe subject to copyright    Report

University of Dundee
Anti-trypanosomatid drug discovery
Field, Mark C.; Horn, David; Fairlamb, Alan H.; Ferguson, Michael A. J.; Gray, David W.;
Read, Kevin D.
Published in:
Nature Reviews Microbiology
DOI:
10.1038/nrmicro.2016.193
Publication date:
2017
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Field, M. C., Horn, D., Fairlamb, A. H., Ferguson, M. A. J., Gray, D. W., Read, K. D., De Rycker, M., Torrie, L. S.,
Wyatt, P. G., Wyllie, S., & Gilbert, I. H. (2017). Anti-trypanosomatid drug discovery: an ongoing challenge and a
continuing need. Nature Reviews Microbiology, 15(4), 217-231. https://doi.org/10.1038/nrmicro.2016.193
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
• Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain.
• You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 26. Aug. 2022

1
Vector-borne diseases series
Antitrypanosomatid drug discovery: an ongoing challenge and a continuing need
Mark C. Field, David Horn, Alan H. Fairlamb, Michael A. J. Ferguson, David W. Gray, Kevin D. Read,
Manu De Rycker, Leah S. Torrie, Paul G. Wyatt, Susan Wyllie and Ian H. Gilbert
Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee, DD1 5EH, UK
Correspondence to I.H.G. i.h.gilbert@dundee.ac.uk
Abstract | The World Health Organization recognizes human African trypanosomiasis, Chagas’
disease and the leishmaniases as neglected tropical diseases. These diseases are caused by parasitic
trypanosomatids and range in severity from mild and self-curing to near invariably fatal. Public
health advances have substantially decreased the impact of these diseases in recent decades, but
alone will not eliminate these diseases. Here we discuss why new drugs against trypanosomatids
are needed, approaches that are under investigation to develop new drugs and why the drug
discovery pipeline remains essentially unfilled. Additionally, we consider the important challenges
to drug discovery strategies and the new technologies that can address them. The combination of
new drugs, new technologies and public health initiatives are essential for the management and
hopefully eventual elimination of trypanosomatid diseases from the human population.
Trypanosomatid parasites cause several neglected diseases of humans and animals,
which range in severity from comparatively mild to near invariably fatal
1,2
. The organisms
responsible for human diseases are: Trypanosoma brucei spp., which cause human African
trypanosomiasis (HAT); T. cruzi, which causes Chagas’ disease; and Leishmania spp., which cause
the leishmaniases. Together, these insect-transmitted parasites threaten millions of people. All of
these organisms have complex life-cycles, with substantial differences in morphology, cell biology
and biochemistry between lifecycle stages and in some cases between species (Box 1).
Control of trypanosomatid diseases has had a mixed history, although public health campaigns
are showing success in many instances. For example, the Southern Cone and Andean initiatives are
tackling Chagas’ disease with a combination of insecticide spraying of dwellings, improved housing,
screening of people in endemic zones and blood bank monitoring
3
. However, South America has
considerable numbers of T. cruzi-infected individuals and many infected individuals have migrated
to North America and Europe, where the disease is non-endemic. In the case of leishmaniasis, co-
infection with Leishmania spp. and HIV can increase the disease burden and severity, and recent
refugee movements from the Middle East into Europe are likely to increase the prevalence of
leishmaniasis in Europe. In the immediate post-colonial period, HAT resurged, but vector control,
active case-finding and treatment have all helped control the disease
4
. However, many

2
trypanosomatid diseases are zoonotic, which will make eradication extremely unlikely. The current
target is elimination, which is still an ambitious goal. Despite progress, trypanosomatid diseases
remain a substantial public health problem and there is an urgent need for new drugs to tackle
them.
None of the available drugs for treatment of trypanosomatid disease (Table 1) are satisfactory
and new drugs are needed, especially those suitable for rural health systems with limited resources.
The current standard of care is monotherapy, with the exception of nifurtimox-eflornithine
combination therapy (NECT) for HAT, although various drug combinations are in clinical trials.
Importantly, many of the current treatments require parenteral administration
5
, and also suffer
from poor efficacy, major side effects and increasing levels of resistance
6-8
. Most of the drugs in use
probably have multiple modes of action, due to acting on multiple parasite targets
9
. Goals for drug
discovery include the development of completely new classes of therapeutics, reduced host toxicity,
improved administration regimens and the development of combination therapies.
Vaccine development is a powerful approach to disease management but remains challenging
in the trypanosomatid diseases due to efficient immune evasion mechanisms, such as antigenic
variation in the African trypanosomes, and the intracellular locations of T. cruzi and Leishmania spp.
in the human host. Progress towards human
10
and canine
11
leishmania vaccines and the challenges
in developing vaccines for HAT
12
and Chagas’ disease
13
have been reviewed recently and will not be
discussed further here.
In this Review, we discuss the potential for the development of new drug therapies against
trypanosomatids. We highlight unique biological features of these parasites that suggest potential
targets, methods used to identify bioactive compounds and consider some of the outcomes of
recent campaigns. We encourage the reader to consider excellent reviews of life cycles, genomes,
pathogenesis and more general aspects of the biology of trypanosomatids published elsewhere
14-
19
.
[H1] Drug discovery
A successful drug discovery campaign typically takes 10-15 years (Fig. 1). High attrition rates,
together with relatively few organizations working on drug discovery for trypanosomatid parasites
mean that the number of new compounds in clinical development is very low (Fig. 2) and unlikely
to meet the clinical need. Ideally, the pipeline would contain multiple new agents that are suitable
for combination therapy. The advantages of combination therapies are manifold: they can increase
the clinical efficacy of treatments; they can reduce side effects by allowing lower dosing of individual
agents; and they can reduce the risk of resistance development. Reducing resistance is critical for
safeguarding whatever new medicines do emerge from the drug discovery pipeline.
Three broad approaches are used for drug discovery against trypanosomatids: (1) target-
based approaches involve screening for inhibitors against a purified protein, for example an enzyme.
Compounds identified through the screening (or structure-based) process are subsequently
optimized to show efficacy in a cellular model; (2) phenotypic approaches involve screening for
growth-inhibitors directly against an intact parasite, usually in an in vitro culture; (3) compound re-

3
positioning is re-deployment of compounds previously developed for an alternative indication as
anti-trypanosomatid therapies.
The drug discovery process is ideally driven by target product profiles (TPPs), which define the
properties required of a drug for clinical application
20-22
. Such factors include: route of
administration (oral, inhaled, intravenous, etc.), acceptable dosing regimen and course of
treatment, acceptable safety and tolerability levels, cost and shelf-life. TPPs allow for the
development of compound progression criteria, which define parameters for compounds at each
stage in the drug discovery process (hit, validated hit, lead, preclinical candidate, etc. see Fig. 1).
Progression criteria include assessment of the physicochemical properties (such as solubility in
physiological media, lipophilicity, molecular weight, hydrogen bond donors and acceptors), potency
(against the molecular target and intact organism), selectivity, chemical and metabolic stability,
pharmacokinetics, efficacy and safety. Additional criteria for parasitic infections can include factors
such as cytocidal activity and the rate of parasite killing. The Drugs for Neglected Diseases Initiative
(DNDi) is a public private partnership that focuses on drug discovery and clinical development for
these organisms. It has developed TPPs and compound progression criteria for trypanosomatid
diseases (www.dndi.org)
21
.
[H1] Target-based approaches
For target-based approaches, the key is careful selection of the most promising molecular
targets. A recent review highlights some examples of target-based drug discovery against
trypanosomatids
23
. For neglected diseases in general, including the trypanosomatid diseases, there
has been very limited success from target-based approaches. This is often due to lack of translation
from inhibition of the target (enzyme) in a purified cell-free context to inhibition of proliferation of
the parasite and/or subsequent activity in an animal disease model. In part, this reflects the absence
of robustly validated targets (for example, enzymes whose activity is essential to the parasite) and
highlights the need for fundamental research into trypanosomatid biology and for thorough genetic
and chemical validation of potential targets
24
. However, this is only part of the problem. As will be
discussed below, an improved understanding of how to translate compounds that are active in vitro
into therapeutics is required, which includes better defining the cellular and animal models (Box 2)
that predict clinical efficacy in humans.
We have published some criteria to help in selection of molecular targets (Box 3)
9,20,24
. Many
target-based drug discovery programmes can be initially viewed as target-validation
25
. It is therefore
vital to obtain proof-of-concept (POC) of anti-parasitic activity for new target-derived chemical
series at the earliest possible stage, ideally both in cellular and animal models, to minimize waste of
resources, should the target fail to progress.
[H3] Drug targets with the highest degree of validation
The best validated drug-target in T. brucei is ornithine decarboxylase (ODC), which is the target
of eflornithine, a drug used clinically for treatment of HAT. Eflornithine is a suicide inhibitor that was
initially developed for the treatment of cancer, but subsequently re-purposed for HAT
26
. Selectivity
is thought to arise from the more rapid turnover of human ODC compared to the trypanosome

4
enzyme
27
, or due to inhibition of trypanothione biosynthesis
28
, which is a metabolite unique to
trypanosomatids.
The enzyme N-myristoyltransferase (NMT) has also been well validated as a molecular target
for HAT
29-31
. In a programme initiated with a high-throughput screen against NMT, a compound
series was identified and subsequently optimized (typified by DDD85646, Fig. 3b) to be active in a
mouse model of the first stage of HAT, which does not involve the central nervous system. There
was strong evidence that the compounds inhibit NMT in cells and that this inhibition kills parasites,
which validates both the target and the mode of action. NMT is also present in humans, but T. brucei
is acutely sensitive to NMT inhibition, probably because endocytosis, which occurs at a very high
rate in T. brucei, is affected. NMT has also been validated as a target in a second stage mouse model
of HAT (K.D.R., personal communication). The challenge with second stage disease is that
compounds need to penetrate the blood brain barrier and achieve therapeutic concentrations in
the central nervous system without causing host toxicity
Very recently the proteasome has been shown to have great potential as a target in all three
types of trypansomatids
32
. This study used a phenotypic approach to develop a parasite-specific,
selective inhibitor (GNF6702) that does not inhibit the human proteasome This is an excellent
example of taking a phenotypic hit and subsequently deconvoluting the target. The initial
experiments to determine the mode of action involved generating compound-resistant T. cruzi
mutants, followed by whole genome sequencing, which revealed mutations in the β4 subunit of the
proteasome. Various additional biochemical experiments demonstrated that GNF6703 specifically
inhibits the chymotrypsin-like activity of the parasite proteasome.
[H3] Biological features of trypanosomatids that might be targeted
Trypanosomatids are one of the most evolutionary divergent eukaryotic lineages from
mammals, a feature that is reflected in their distinct biology (Fig. 3a). Conversely, there are many
similarities between T. brucei, T. cruzi and Leishmania spp. and many molecular mechanisms are
conserved between all three lineages. Trypanosomatid-specific metabolic and cellular pathways
(discussed below) should represent excellent drug targets as specificity should be an easier criterion
to control, but no candidate drugs have been developed that inhibit such targets. In fact, most
potential trypanosome-specific targets remain unexplored for drug discovery and/or are of
unknown druggability. Ironically, the best validated targets in trypanosomatids are one repurposed
from oncology (ODC) and two pan-eukaryotic essential targets (NMT and the proteasome),
discussed above.
Uniquely, trypanosomatids package the first six or seven enzymes of glycolysis into the
glycosome, a specialized form of the peroxisome. Glycolysis is especially important for the
bloodstream forms of African trypanosomes, which rely exclusively on this pathway for ATP
production. The compartmentalization of glycolysis in trypanosomatids is accompanied by
fundamental differences in allosteric regulation of the pathway compared to most other
eukaryotes. Because of this, phosphofructokinase, for example, is being pursued as a target
33
.
However, computational modelling of glycolysis suggests that there is little prospect of killing
trypanosomes by suppressing glycolysis unless inhibition is irreversible or uncompetitive, due to the

Citations
More filters
Journal ArticleDOI
25 Jul 2018-Nature
TL;DR: Some of the challenges involved in developing new drugs to treatfectious tropical diseases are discussed, and there is still a long way to go.
Abstract: Infectious tropical diseases have a huge effect in terms of mortality and morbidity, and impose a heavy economic burden on affected countries These diseases predominantly affect the world's poorest people Currently available drugs are inadequate for the majority of these diseases, and there is an urgent need for new treatments This Review discusses some of the challenges involved in developing new drugs to treat these diseases and highlights recent progress While there have been notable successes, there is still a long way to go

145 citations


Cites background from "Anti-trypanosomatid drug discovery:..."

  • ...This area has recently been reviewed in detail 60 ....

    [...]

Journal ArticleDOI
TL;DR: An optimized genome-scale gain-of-function library in trypanosomes was developed and used to identify the benzoxaborole target and reveal inhibition of mRNA maturation as the mode of action of the trypanocidal Benzoxaboroles.
Abstract: African trypanosomes cause lethal and neglected tropical diseases, known as sleeping sickness in humans and nagana in animals Current therapies are limited, but fortunately, promising therapies are in advanced clinical and veterinary development, including acoziborole (AN5568 or SCYX-7158) and AN11736, respectively These benzoxaboroles will likely be key to the World Health Organization’s target of disease control by 2030 Their mode of action was previously unknown We have developed a high-coverage overexpression library and use it here to explore drug mode of action in Trypanosoma brucei Initially, an inhibitor with a known target was used to select for drug resistance and to test massive parallel library screening and genome-wide mapping; this effectively identified the known target and validated the approach Subsequently, the overexpression screening approach was used to identify the target of the benzoxaboroles, Cleavage and Polyadenylation Specificity Factor 3 (CPSF3, Tb92741340) We validated the CPSF3 endonuclease as the target, using independent overexpression strains Knockdown provided genetic validation of CPSF3 as essential, and GFP tagging confirmed the expected nuclear localization Molecular docking and CRISPR-Cas9-based editing demonstrated how acoziborole can specifically block the active site and mRNA processing by parasite, but not host CPSF3 Thus, our findings provide both genetic and chemical validation for CPSF3 as an important drug target in trypanosomes and reveal inhibition of mRNA maturation as the mode of action of the trypanocidal benzoxaboroles Understanding the mechanism of action of benzoxaborole-based therapies can assist development of improved therapies, as well as the prediction and monitoring of resistance, if or when it arises

85 citations


Cites background from "Anti-trypanosomatid drug discovery:..."

  • ...The closely related parasites that cause acute and chronic forms of the human disease in Eastern and Western Africa are Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense, respectively (1)....

    [...]

Journal ArticleDOI
TL;DR: This review discusses not only scientific and non-scientific bottlenecks in drug development, but also the central role of public-private partnerships for a successful campaign for novel treatment options against this devastating disease.
Abstract: Tritryps diseases are devastating parasitic neglected infections caused by Leishmania spp., Trypanosoma cruzi and Trypanosoma brucei subspecies. Together, these parasites affect more than 30 million people worldwide and cause high mortality and morbidity. Leishmaniasis comprises a complex group of diseases with clinical manifestation ranging from cutaneous lesions to systemic visceral damage. Antimonials, the first-choice drugs used to treat leishmaniasis, lead to high toxicity and carry significant contraindications limiting its use. Drug-resistant parasite strains are also a matter for increasing concern, especially in areas with very limited resources. The current scenario calls for novel and/or improvement of existing therapeutics as key research priorities in the field. Although several studies have shown advances in drug discovery towards leishmaniasis in recent years, key knowledge gaps in drug discovery pipelines still need to be addressed. In this review we discuss not only scientific and non-scientific bottlenecks in drug development, but also the central role of public-private partnerships for a successful campaign for novel treatment options against this devastating disease.

84 citations


Cites background from "Anti-trypanosomatid drug discovery:..."

  • ...When applied properly, it can play a central role in the drug discovery pipeline (Wyatt et al., 2011; Field et al., 2017)....

    [...]

Journal ArticleDOI
TL;DR: This link between melarsoprol and AQP2 illustrates how a drug transporter can improve drug selectivity but, at the same time, highlights the risk of resistance when the drug uptake mechanism is dispensable for parasite viability and virulence.

81 citations


Cites background from "Anti-trypanosomatid drug discovery:..."

  • ...To conclude, insights into drug mode of action and resistance mechanisms facilitate drug discovery and development and the design of optimal (combination) therapies and dosing strategies [89]....

    [...]

Journal ArticleDOI
TL;DR: The ongoing endeavor at the global scale will ultimately benefit the patients, the countries they are living and, hopefully, the manufacturers who provide new preventive, diagnostic and therapeutic products.
Abstract: Neglected tropical diseases (NTDs) are closely related to poverty and affect over a billion people in developing countries. The unmet treatment needs cause high mortality and disability thereby imposing a huge burden with severe social and economic consequences. Although coordinated by the World Health Organization, various philanthropic organizations, national governments and the pharmaceutical industry have been making efforts in improving the situation, the control of NTDs is still inadequate and extremely difficult today. The lack of safe, effective and affordable medicines is a key contributing factor. This paper reviews the recent advances and some of the challenges that we are facing in the fight against NTDs. In recent years, a number of innovations have demonstrated propensity to promote drug discovery and development for NTDs. Implementation of multilateral collaborations leads to continued efforts and plays a crucial role in drug discovery. Proactive approaches and advanced technologies are urgently needed in drug innovation for NTDs. However, the control and elimination of NTDs remain a formidable task as it requires persistent international cooperation to make sustainable progresses for a long period of time. Some currently employed strategies were proposed and verified to be successful, which involve both mechanisms of ‘Push’ which aims at cutting the cost of research and development for industry and ‘Pull’ which aims at increasing market attractiveness. Coupled to this effort should be the exercise of shared responsibility globally to reduce risks, overcome obstacles and maximize benefits. Since NTDs are closely associated with poverty, it is absolutely essential that the stakeholders take concerted and long-term measures to meet multifaceted challenges by alleviating extreme poverty, strengthening social intervention, adapting climate changes, providing effective monitoring and ensuring timely delivery. The ongoing endeavor at the global scale will ultimately benefit the patients, the countries they are living and, hopefully, the manufacturers who provide new preventive, diagnostic and therapeutic products.

70 citations


Cites background from "Anti-trypanosomatid drug discovery:..."

  • ...Cellular assays are representatives of certain in vivo situation and suitable to preliminary evaluation of pharmacokinetic and/or pharmacodynamic profiles [47]....

    [...]

References
More filters
Journal ArticleDOI
03 Jan 2014-Science
TL;DR: In this paper, a pooled, loss-of-function genetic screening approach suitable for both positive and negative selection that uses a genome-scale lentiviral single-guide RNA (sgRNA) library was described.
Abstract: The bacterial clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 system for genome editing has greatly expanded the toolbox for mammalian genetics, enabling the rapid generation of isogenic cell lines and mice with modified alleles. Here, we describe a pooled, loss-of-function genetic screening approach suitable for both positive and negative selection that uses a genome-scale lentiviral single-guide RNA (sgRNA) library. sgRNA expression cassettes were stably integrated into the genome, which enabled a complex mutant pool to be tracked by massively parallel sequencing. We used a library containing 73,000 sgRNAs to generate knockout collections and performed screens in two human cell lines. A screen for resistance to the nucleotide analog 6-thioguanine identified all expected members of the DNA mismatch repair pathway, whereas another for the DNA topoisomerase II ( TOP2A ) poison etoposide identified TOP2A , as expected, and also cyclin-dependent kinase 6, CDK6. A negative selection screen for essential genes identified numerous gene sets corresponding to fundamental processes. Last, we show that sgRNA efficiency is associated with specific sequence motifs, enabling the prediction of more effective sgRNAs. Collectively, these results establish Cas9/sgRNA screens as a powerful tool for systematic genetic analysis in mammalian cells.

2,487 citations

Journal ArticleDOI
TL;DR: Repositioning existing drugs for new indications could deliver the productivity increases that the industry needs while shifting the locus of production to biotechnology companies.
Abstract: Biopharmaceutical companies attempting to increase productivity through novel discovery technologies have fallen short of achieving the desired results. Repositioning existing drugs for new indications could deliver the productivity increases that the industry needs while shifting the locus of production to biotechnology companies. More and more companies are scanning the existing pharmacopoeia for repositioning candidates, and the number of repositioning success stories is increasing.

2,484 citations

01 Dec 2013
TL;DR: A pooled, loss-of-function genetic screening approach suitable for both positive and negative selection that uses a genome-scale lentiviral single-guide RNA (sgRNA) library is described and it is shown that sgRNA efficiency is associated with specific sequence motifs, enabling the prediction of more effective sgRNAs.
Abstract: The bacterial CRISPR/Cas9 system for genome editing has greatly expanded the toolbox for mammalian genetics, enabling the rapid generation of isogenic cell lines and mice with modified alleles. Here, we describe a pooled, loss-of-function genetic screening approach suitable for both positive and negative selection that uses a genome-scale lentiviral single guide RNA (sgRNA) library. sgRNA expression cassettes were stably integrated into the genome, which enabled a complex mutant pool to be tracked by massively parallel sequencing. We used a library containing 73,000 sgRNAs to generate knockout collections and performed screens in two human cell lines. A screen for resistance to the nucleotide analog 6-thioguanine identified all expected members of the DNA mismatch repair pathway, while another for the DNA topoisomerase II (TOP2A) poison etoposide identified TOP2A, as expected, and also cyclin-dependent kinase 6, CDK6. A negative selection screen for essential genes identified numerous gene sets corresponding to fundamental processes. Finally, we show that sgRNA efficiency is associated with specific sequence motifs, enabling the prediction of more effective sgRNAs. Collectively, these results establish Cas9/ sgRNA screens as a powerful tool for systematic genetic analysis in mammalian cells.

2,130 citations

Journal ArticleDOI
TL;DR: It is postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.
Abstract: Preclinical strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biologic-based approaches. To investigate whether some strategies have been more successful than others in the discovery of new drugs, we analysed the discovery strategies and the molecular mechanism of action (MMOA) for new molecular entities and new biologics that were approved by the US Food and Drug Administration between 1999 and 2008. Out of the 259 agents that were approved, 75 were first-in-class drugs with new MMOAs, and out of these, 50 (67%) were small molecules and 25 (33%) were biologics. The results also show that the contribution of phenotypic screening to the discovery of first-in-class small-molecule drugs exceeded that of target-based approaches — with 28 and 17 of these drugs coming from the two approaches, respectively — in an era in which the major focus was on target-based approaches. We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.

1,552 citations

Journal ArticleDOI
TL;DR: It is essential that there be a strategy to prevent the emergence of resistance to new drugs; combination therapy, monitoring of therapy, and improved diagnostics could play an essential role in this strategy.
Abstract: Leishmaniasis is a complex disease, with visceral and cutaneous manifestations, and is caused by over 15 different species of the protozoan parasite genus Leishmania. There are significant differences in the sensitivity of these species both to the standard drugs, for example, pentavalent antimonials and miltefosine, and those on clinical trial, for example, paromomycin. Over 60% of patients with visceral leishmaniasis in Bihar State, India, do not respond to treatment with pentavalent antimonials. This is now considered to be due to acquired resistance. Although this class of drugs has been used for over 60 years for leishmaniasis treatment, it is only in the past 2 years that the mechanisms of action and resistance have been identified, related to drug metabolism, thiol metabolism, and drug efflux. With the introduction of new therapies, including miltefosine in 2002 and paromomycin in 2005-2006, it is essential that there be a strategy to prevent the emergence of resistance to new drugs; combination therapy, monitoring of therapy, and improved diagnostics could play an essential role in this strategy.

1,450 citations

Related Papers (5)